Coronary Artery Bypass Surgery Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG)Surgery
This clinical trial will investigate the safety and effectiveness of IK-1001 (the liquid
form of sodium sulfide) when used in Coronary Artery Bypass Graft (CABG) patients to
potentially reduce the damage done to the heart during surgery.
This study has 2 parts. Part 1 will first test 36 subjects at different doses (amount) of
the study drug. There will be 6 different groups of 6 subjects each that will receive the
study drug or a placebo. A placebo is a substance that will be prepared to look like the
study drug but will contain no active ingredients. In Part 1, five subjects from each group
will receive study drug (IK-1001) and one will receive a placebo. This first part of this
study is also a dose (amount) escalation. This means that each group will be receiving a
different dose of the study drug. The first group will receive the lowest dose, the second
group will receive a slightly higher dose, and the third group a slightly higher dose until
all six groups has been tested. You can not choose which group you will be in but prior to
starting each new dose level, the data (information) from the previous dose level will have
been reviewed by a group of qualified individuals to determine if it is safe to proceed to
the next highest dose level.
Part 2 will expand the study and will treat at least 158 (and up to 632) more subjects at a
dose level that has been deemed safe from information collected from Part 1. Subjects in
Part 2 of the study will have a 1 in 2 (50%) chance of receiving the study drug or placebo.
Whether the subject gets study drug or the placebo will be randomly assigned (like the toss
of a coin).
The study drug or placebo will be given as an intravenous infusion (into the vein) for six
hours while the subject is having their CABG surgery.
The subjects will be followed up for 6 months after their CABG surgery.
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter, dose
escalation and dose-expansion, study that will evaluate safety, PK, and POC-efficacy of
IK-1001 in subjects undergoing on pump CABG surgery who are at an increased risk for I/R
mediated tissue damage.
Study subjects will undergo planned CABG surgery with cardiopulmonary bypass. The study will
be conducted in two parts. Part 1 of the study will involve the dose escalation to evaluate
safety, PK, and preliminary efficacy of IK-1001. Up to 36 eligible subjects will be enrolled
into the Part 1 portion and randomized to receive either placebo (n = 6) or IK-1001 (n = 30)
at 6 dose escalating levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6
hours.
The study drug administration will begin in the operating room after the induction of
anesthesia and prior to the surgical incision.
After safety, efficacy, and PK data have been evaluated in Part 1, the optimum dose will be
determined and this dose will be expanded in Part 2. Initially up to 158 eligible subjects
will be randomized to receive either IK-1001 or placebo at a 1:1 ratio. Part 2 aims to
further establish safety, PK as well as POC efficacy.
In the event that none of the 4 primary endpoints reach at least a 15% decline as compared
with placebo, the Sponsor may decide to amend the protocol to explore a higher dose. After 6
subjects have been dosed at this higher dose level, the data will be reviewed by the Sponsor
or designee for safety and PK and the remaining subjects will then be enrolled. If the
safety and PK data are favorable, the study will be completed at this higher dose level.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05139108 -
TEE Monitoring and the Incidence of Postoperative Acute Kidney Injury in Coronary Artery Bypass Grafting
|
||
Completed |
NCT04523064 -
POST-CABGDM: Empagliflozin in Perioperative CABG
|
Phase 4 | |
Not yet recruiting |
NCT05540249 -
Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG
|
N/A | |
Completed |
NCT01467232 -
IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting
|
Phase 2 | |
Completed |
NCT04631809 -
Computed Tomography Coronary Angiography in Patients With a Previous Coronary Artery Bypass Graft Surgery Trial
|
N/A | |
Completed |
NCT00073580 -
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
|
Phase 3 | |
Terminated |
NCT03346278 -
Text Message Intervention to Improve Cardiac Rehab Participation
|
N/A | |
Completed |
NCT00303641 -
Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients
|
Phase 1 | |
Completed |
NCT03823521 -
Observational Study to Investigate the Effects of Training on the Administration of Cardioplexolâ„¢
|
Phase 3 | |
Terminated |
NCT00789399 -
A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
|
N/A | |
Completed |
NCT02592824 -
Glutamate for Metabolic Intervention in Coronary Surgery II
|
Phase 3 | |
Not yet recruiting |
NCT05079724 -
Acute Kidney Injury After Cardiac Surgery
|
||
Withdrawn |
NCT04379947 -
Preoperative Use of Fractional Flow Reserve in CABG Use and Effectiveness of FFR-based CABG in Real-life Practice
|
||
Recruiting |
NCT01386229 -
A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery
|
Phase 4 | |
Completed |
NCT00653042 -
Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA
|
Phase 2 | |
Completed |
NCT00318227 -
Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients
|
N/A | |
Completed |
NCT00372671 -
Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation
|
Phase 3 | |
Completed |
NCT00209521 -
Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery
|
Phase 2 | |
Not yet recruiting |
NCT05396690 -
Safety and Efficacy of Remimazolam in OPCAB Surgery
|
N/A | |
Recruiting |
NCT05411445 -
Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery
|